US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Panion’s board of directors evaluates development plan, terminates study before any enrolment, and withdraws INAD application to avoid substantial fees.

At a board meeting in Panion AB on September 6 2019, the development plan for Panion’s gene therapy product for treatment of drug-refractory epilepsy was discussed. The dog study at the veterinary clinic LIVS in New York is currently on hold. The board of directors decided to terminate the current study plan. Panion has had an excellent cooperation with the clinic and for clarity, no negative event has occurred in the planning of the study or with the product. As a consequence of the terminated study in dogs, the Board of directors decided to withdraw the open Investigational New Animal

Panion’s Q2-19 report, change of CFO, and end of contract for Business Development Director

The board of Panion Animal Health AB (“Panion”) adopted the Q2-19 report on the 29.th of August 2019. At the same meeting, the board took decisions that reflects the strategy for Panion subsequent to CombiGene becoming the major shareholder and the change of members of Panion’s board; · Panion’s Business Development Director, Carlos N. Velez, was thanked for valuable work and input over the years and his contract will be terminated according to the agreement. · The CFO of Panion, Katarina Holm, Er Redovisning i Skåne AB, was thanked for excellent work in the time she served

2019 Q2 report, Period January-June for Panion Animal Health AB

Period April-June · Net sales: kSEK 0 (0). · Operating profit: kSEK -2 767 (-1 299). · Earnings per share: SEK -0,12 (-0,08). · Liquidity at the end of the period: kSEK 586 (15). Period January-June · Net sales: kSEK 0 (0). · Operating profit: kSEK -4 430 (-1 996). · Earnings per share: SEK -0,19 (-0,08). · Liquidity at the end of the period: kSEK 586 (15). Significant events after the end of the period:On July 10, 2019, it was announced that the shareholders of Panion Animal Health AB have accepted the offer from CombiGene AB with an acceptance rate

New board members in Panion

Communication from the Extraordinary General Meeting in Panion Animal Health AB held on the 20.th of August 2019. Panion’s EGM decided to adopt the proposals to make changes in the board and appointed auditors as presented in the attached communications (English and Swedish). The new board consists of Arne Ferstad, Jan Nilsson, and Lars Thunberg. The board has held a constitutional meeting and appointed Arne Ferstad as chairman of the board. Read more in attached documents

Information about Panion’s decisions based on the outcome of Combigene’s bid

Panion’s board and directors held a board meeting on the 12.th of July 2019 to discuss the outcome of Combigene’s offer to the shareholders in Panion.Panion’s board announces the following decisions based on Combigene’s fulfilling of the offer to take over 88.35% of shares and 84.91% of warrants in Panion with the transaction-date starting on the 25.th of July 2019. Combigene has expressed a request for an extraordinary general assembly (EGA) and this will be planned for the 20.th of August 2019. An official announcement will follow later. The prospect prepared earlier this year for a

Combigene has decided to carry through the bid to shareholders in Panion

The shareholders of Panion Animal Health AB have accepted the offer from Combigene AB with an acceptance rate below 90%. The exact number is expected to be announced tomorrow the 11.th of July 2019. Despite not reaching the intended 90% of acceptance and with reference to the press release from Combigene AB, link , Combigene’s board has decided to complete the bid and end the acceptance period and that the non-cash shares issue is carried out. The board and management of Panion have

Final report from dog safety study released

Panion Animal Health AB develops a new treatment for dogs with epilepsy, based on CombiGene’s gene therapy vector for human epilepsy.In spring 2018, a safety study in dogs was started under the lead of Associate Professor David Woldbye, Department of Neuroscience, University of Copenhagen. The animal phase of the study was finalized in August 2018, whereas the laboratory testing and imaging and the pathology examinations were performed during fall and winter. The final report has now been released. The study tested the health reactions and potential adverse effects of the intracranial

2019 Q1 report, Period January-March for Panion Animal Health AB

Period January-March• Net sales: kSEK 0 (0).• Operating profit: kSEK -1 663 (-697).• Earnings per share: SEK -0,07 (-0,05).• Liquidity at the end of the period: kSEK 4 961 (2 708). Significant events after the end of the period:• On April 18, 2019, CombiGene AB (publ) announced a public offer to the holders of shares and warrants of series TO1 in Panion Animal Health AB (publ) to tender all their shares and warrants to CombiGene. The full offer can be viewed on Panion’s and/or CombiGene’s websites. The acceptance period for the offer is expected to commence on or around 23 May

Communication from the Annual General Meeting in Panion Animal Health AB

Today, 23 April 2019, an Annual General Meeting (AGM) was held in Panion Animal Health AB (publ) (the “Company”). A summary of the resolutions follows.Approval of profit and loss accounts and balance sheetsThe profit and loss accounts and balance sheets were approved by the AGM. Allocation of profitsThe AGM decided to allocate the Company’s results in accordance with the proposal from the board of directors. The AGM also decided that no dividend should be distributed for the financial year 2018. LiabilityThe AGM decided to discharge each of the members of the board of directors

CombiGene announces a public offer to the holders of shares and warrants of series TO1 in Panion Animal Health

Background CombiGene AB (publ) (“CombiGene”) today announces a public offer to the holders of shares (“Shares”) and warrants of series TO1 with ISIN code SE0011205343 (“Warrants”) in Panion Animal Health AB (publ) (“Panion” or the “Company”) to tender all their Shares and Warrants to CombiGene (the “Offer”). The Shares and the Warrants are listed on Spotlight Stock Market (“Spotlight”). The Offer in brief ·  CombiGene offers 0.5426 shares in CombiGene for each Share (the “Share Purchase Price”) and 0.0559 shares in CombiGene for each Warrant (the “Warrant Purchase Price”).[1]

PM Technical investigator meeting in Copenhagen

Panion develops a gene therapy treatment for dogs with epilepsy. The clinical trial in dogs with real epilepsy will take place in the large investigator clinic, Long Island Veterinary Specialists (LIVS) in New York, USA. The study procedures are advancing well in accordance with the plan. The vector material is produced and undergoing testing procedures. The previous two studies in dogs related to Panion’s gene therapy product documented the safety of the treatment and procedures. They were both conducted in the University of Copenhagen under the lead of associate professor David Woldbye,

Good progress of Panion’s dog study and the chairman’s report from London

Panion Animal Health AB develops an innovative gene therapy treatment for epilepsy in dogs. The development product CG01-canine has just entered the clinical phase with an ongoing dog study in USA. This study will explore the efficacy of the product in drug-refractory epilepsy cases in privately owned dogs and it builds on two earlier dogs studies conducted with healthy animals to show the safety of the product. The safety studies showed a very good safety profile of the product and provide a good basis to trust that the future product authorization will not be hindered by adverse events

New advisory board member

Panion Animal Health AB develops a gene therapy product for treatment of epilepsy in dogs, for which the clinical phase has started. Panion’s highly competent advisory board has now been expanded with the fourth member, Dr. Dominic J. Marino, DVM, DACVS, DACCT, CCRP, who is the lead investigator of the ongoing clinical study in dogs. Dr. Dominic J. Marino is an experienced veterinary neurologist and neurosurgeon He is the Chief of Staff of Long Island Veterinary Specialists, the Director of the Canine Chiari Institute, and a founding board member of the New York Veterinary Foundation.

Panion presents at Animal Health Investment Europe, London, on 27 February 2019

Panion Animal Health AB develops an innovative treatment for epilepsy in dogs and has just started the clinical phase. Panion has been selected to present its business plan at the 2019 Animal Health Investment Forum as part of the Innovation Showcase of the year, in the programme on translational technology from human-to-veterinary pharma. Panion’s chairman of the board, Lars Thunberg, will inform the audience about the promising business idea in veterinary medicines and the progress over the last two years. The focus will be on the commercial elements of Panion’s business plan and

2018 Q4 report, Period October-December

Period October-December · Net sales: kSEK 0 (0) · Operating profit: kSEK -2 184 (-854) · Earnings per share: SEK -0,10 (-0,06) · Liquidity at the end of the period: kSEK 306 (2 124) Period January-December · Net sales: kSEK 0 (0) · Operating profit: kSEK -4 716 (-4 200) · Earnings per share: SEK -0,25 (-0,32) · Liquidity at the end of the period: kSEK 306 (2 124) CEO statementPanion’s epilepsy project for dogs has taken some big steps forward and I want to start with thanking all our investors for their support and trust in our idea. During the year,

Panion attracts attention from animal health media

Panion is attracting interest from the agribusiness intelligence and animal health media Animal Pharm, where journalist Sian Lazell yesterday, 31.st of January 2019, noted the news on financing of the development program from Panion: https://bit.ly/2t1tgeK “Panion secures extra funding to back R&D. The financing round was carried out through the issuance of notes with warrants attached to Yorkville Advisors Global, that have a principal amount of SEK 100,000 each. Swedish firm Panion plans to use the capital to advance its R&D efforts. Panion is developing a gene therapy for epilepsy in

Panion draws down a second tranche of convertibles of SEK 2 million

Panion Animal Health AB ("Panion") draws down a second tranche from the investment fund managed by Yorkville Advisors Global ("Yorkville").Panion entered into a financing agreement with Yorkville which was announced on 9 January 2018 (the "Agreement") (see press release dated 9 January 2018). On 23 January 2019, Panion’s board of directors decided to draw down a second tranche pursuant to the Agreement as well as the issuance of the Notes and warrants under this second tranche. The issuance is within the limitations of the authorization from the shareholder's meeting held on 29 May 2018.

Fee waiver 2019 and Categorical exclusion

Fee waiver 2019The company has re-applied for a fee waiver for 2019 and received positive answer from US-FDA again, as for fiscal years 2017 and 2018. This means that also for 2019, the company must not pay the very high fee for a running application to the FDA. The fee waiver is granted as a result of the MUMS determination (Minor Use Minor Species) for the product. Categorical exclusion for environmental assessmentPanion has also applied to US-FDA for claiming a so-called “Categorical Exclusion” (CE) under 21 CFR 25.33(e) for the investigational use of CG-01-canine with regards to

The rights issue in Panion Animal Health AB has been registered by the Swedish Companies Registration Office

The rights issue which was decided by the Board of Panion Animal Health AB, with the authorization of the Annual General Meeting of 29 May 2018, has now been registered by the Swedish Companies Registration Office. Shares and share capital after the registration by the Swedish Companies Registration Office amount to SEK 1,137,110.723254 divided into 24,399,487 shares. Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic

Panion presents at Animal Health Investment Europe, in London 26-27 February 2019

Panion Animal Health AB develops an innovative treatment for epilepsy in dogs and has just started the clinical phase. The product in development is based on the gene therapy platform for human epilepsy from CombiGene AB. Panion has been selected as one of 24 finalist companies to present at the 2019 Animal Health Investment Innovation Showcase. Panion’s chairman of the board, Lars Thunberg, and CEO, Anja Holm, will address the audience with a focus on the commercial elements of Panion’s business and plans in the programme on translational technology from human-to-veterinary pharma.

The rights issue was subscribed for at 17.4 percent

The rights issue in Panion Animal Health AB was subscribed for approximately SEK 1.3 million, corresponding to approximately 17.4 percent of the issue. Existing shareholders with preferential rights subscribed for 1,294,491 shares, corresponding to approximately 16.8 percent. Panion is thus allocated approximately SEK 1.3 million before issue costs of approximately SEK 150,000. By subscription and allotment 1,337,365 shares are issued. Settlement notes are scheduled to be sent out on January 2, 2019. Shares and share capital after the rights issue amount to SEK 1,137,110,723 divided into 24,

There are no items matching the current filter
There are no more items matching the current filter
Back to top